Claims for Patent: 12,208,100

Summary for Patent: 12,208,100

Title:	Dosing regimens associated with extended release paliperidone injectable formulations
Abstract:	The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.
Inventor(s):	Srihari Gopal, Raja Venkatasubramanian, Huybrecht T'Jollyn
Assignee:	Janssen Pharmaceutica NV
Application Number:	US17/738,422
Patent Claims:	1. A method for administering paliperidone palmitate to a patient in need of treatment for psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar disorder who has been administered a first dose of a six-month paliperidone palmitate extended-release injectable suspension (PP6M), comprising administering a second dose of the PP6M to a deltoid or gluteal muscle of the patient within a dosing window of a dosing regimen for the PP6M that is up to two weeks before or three weeks after a time that is six months after administration of the first dose such that the patient has not missed a dose based on the regimen, wherein there is no intervening dose of paliperidone palmitate between the first dose and the second dose; wherein the first dose comprises about 1092 mg or about 1560 mg paliperidone palmitate; and the second dose comprises about 1092 mg or about 1560 mg paliperidone palmitate; and wherein the PP6M comprises about 280 mg/mL to about 350 mg/mL of the paliperidone palmitate. 2. The method of claim 1, wherein the patient is in need of treatment for schizophrenia. 3. The method of claim 2, wherein the first and second dose of PP6M are administered to a gluteal muscle of the patient. 4. The method of claim 3, wherein the PP6M comprises about 312 mg/ml of paliperidone palmitate. 5. The method of claim 3, wherein the PP6M further comprises: about 8 mg/mL to about 12 mg/mL of a wetting agent; one or more buffering agents; about 65 mg/mL to about 85 mg/mL of a suspending agent; and water q.s. ad 100%. 6. The method of claim 5, wherein the PP6M is from about pH 6.0 to about pH 8.0. 7. The method of claim 6, wherein the one or more buffering agents comprise citric acid monohydrate, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, or sodium hydroxide. 8. The method of claim 5, wherein the PP6M comprises: about 312 mg/mL of paliperidone palmitate; about 10 mg/mL of the wetting agent, wherein the wetting agent is polysorbate 20; and about 75 mg/mL of the suspending agent, wherein the suspending agent is polyethylene glycol 4000. 9. The method of claim 1, wherein the patient has a steady state paliperidone plasma concentration at the time of the first dose. 10. A method for administering paliperidone palmitate to a patient in need of treatment for schizophrenia who has been treated with either a one-month paliperidone palmitate extended-release injectable suspension (PP1M) or a three-month paliperidone palmitate extended-release injectable suspension (PP3M), comprising administering to the patient in need thereof a last dose of the PPIM or the PP3M and then administering an initial dose of a six-month paliperidone palmitate extended-release injectable suspension (PP6M) to a gluteal muscle of the patient in a single injection, wherein the patient has been treated with the PP1M for at least four months, or the patient has been treated with the PP3M for at least one 3-month interval, and wherein: when the patient has been treated with the PP1M for at least four months, the initial dose of the PP6M is administered 1 month +7 days after the last dose of the PP1M is administered, and when the last dose of the PP1M comprises 156 mg of paliperidone palmitate, the initial dose of the PP6M comprises 1092 mg of paliperidone palmitate, and when the last dose of the PPIM comprises 234 mg of paliperidone palmitate, the initial dose of the PP6M comprises 1560 mg of paliperidone palmitate; or when the patient has been treated with the PP3M for at least one 3-month interval, the initial dose of the PP6M is administered 3 months +14 days after the last dose of the PP3M is administered, and when the last dose of the PP3M comprises 546 mg of paliperidone palmitate, the initial dose of the PP6M comprises 1092 mg of paliperidone palmitate; and when the last dose of the PP3M comprises 819 mg of paliperidone palmitate, the initial dose of the PP6M comprises 1560 mg of paliperidone palmitate; and, subsequent to the initial dose, administering a first dose of the PP6M to a gluteal muscle of the patient in a single injection and administering a second dose of the PP6M in a gluteal muscle of the patient in a single injection within a dosing window of a dosing regimen for the PP6M that is up to two weeks before or three weeks after a time that is six months after administration of the first dose such that the patient has not missed a dose based on the regimen, wherein there is no intervening dose of paliperidone palmitate between the first dose and the second dose; wherein the first dose comprises 1092 mg or 1560 mg paliperidone palmitate; and the second dose comprises 1092 mg or 1560 mg paliperidone palmitate; and wherein the PP6M comprises 312 mg/mL of paliperidone palmitate. 11. The method of claim 10, wherein the PP6M is in a pre-filled syringe having a tip cap and a thin-walled 20 gauge, 1.5 inch needle. 12. The method of claim 11, wherein the syringe is shaken with the tip cap pointing up for at least 15 seconds, and, after a rest, is shaken again for another 15seconds before administration of the PP6M. 13. The method of claim 10, wherein the PP1M comprises: 156 mg/ml of paliperidone palmitate; 8 mg/mL to 16 mg/ml of a wetting agent; one or more buffering agents; 20 mg/mL to 40 mg/ml of a suspending agent; and water q.s. ad 100%; and wherein the PP3M comprises 312 mg/ml of paliperidone palmitate and the PP3M and PP6M each comprise: 8 mg/mL to 12 mg/mL of a wetting agent; one or more buffering agents; 65 mg/mL to 85 mg/mL of a suspending agent; and water q.s. ad 100%, and wherein the PP1M, PP3M, and PP6M are each from pH 6.0 to pH 8.0. 14. The method of claim 13, wherein the one or more buffering agents comprise citric acid monohydrate, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, or sodium hydroxide. 15. The method of claim 14, wherein the PP1M comprises: 12 mg/mL of the wetting agent, wherein the wetting agent is polysorbate 20; and 30 mg/mL of the suspending agent, wherein the suspending agent is polyethylene glycol 4000; and wherein the PP3M and PP6M each comprise: 10 mg/mL of the wetting agent, wherein the wetting agent is polysorbate 20; and 75 mg/mL of the suspending agent, wherein the suspending agent is polyethylene glycol 4000. 16. The method of claim 1, wherein the first dose of the PP6M comprises about 1092mg paliperidone palmitate; and the second dose of the PP6M comprises about 1560 mg paliperidone palmitate. 17. The method of claim 1, wherein the first dose of the PP6M comprises about 1560mg paliperidone palmitate; and the second dose of the PP6M comprises about 1092 mg paliperidone palmitate. 18. The method of claim 4, wherein the first dose of the PP6M comprises about 1092mg paliperidone palmitate; and the second dose of the PP6M comprises about 1560 mg paliperidone palmitate. 19. The method of claim 4, wherein the first dose of the PP6M comprises about 1560mg paliperidone palmitate; and the second dose of the PP6M comprises about 1092 mg paliperidone palmitate. 20. The method of claim 10, wherein the patient has been treated with the PP1M prior to administering the initial dose of the PP6M. 21. The method of claim 10, wherein the patient has been treated with the PP3M prior to administering the initial dose of the PP6M. 22. The method of claim 10, wherein the first dose of the PP6M comprises 1092 mg paliperidone palmitate; and the second dose of the PP6M comprises 1092 mg paliperidone palmitate. 23. The method of claim 10, wherein the first dose of the PP6M comprises 1560 mg paliperidone palmitate; and the second dose of the PP6M comprises 1560 mg paliperidone palmitate. 24. The method of claim 10, wherein the first dose of the PP6M comprises 1092 mg paliperidone palmitate; and the second dose of the PP6M comprises 1560 mg paliperidone palmitate. 25. The method of claim 10, wherein the first dose of the PP6M comprises 1560 mg paliperidone palmitate; and the second dose of the PP6M comprises 1092 mg paliperidone palmitate.